TICKERNERD
Menu
GHGHHealthcare · Diagnostics & Research

GH Stock Forecast: Guardant Health, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$163
+1.12% on the day

The 25 Wall Street analysts covering Guardant Health, Inc. hold a median 12-month price target of $195 — +19.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 8 Sept 2026 — in the lower half.

Market cap
$21.7B
Ticker Nerd rank
48 / 100
Median analyst target
$195
Analysts covering
25
Revenue$335.0M+44.3% y/y
Operating income−$129.1M
Net income−$120.1M
Free cash flow−$69.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.0%
1M
−3.4%
YTD
+59.4%
1Y
+173.9%
From 52W high
−4.8%
From 52W low
+197.1%
$55
$171
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Guardant Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Volatility
70
Growth
62
Quality
60
Revisions
56
Accruals
55
Value
43
Issuance
13
Size
10

Momentum (99): The shares have been drifting up relative to others.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Oct 25Jan 26Apr 26Jul 26GHHigh $225Median $195Low $105

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says25 analysts
24 Buy0 Hold1 Sell
Low $105Median $195High $225

The green dot is the last close — the median target sits +19.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
8 Sept 2026Rothschild & CoInitiatesBuy$203
2 Sept 2026BTIGReiteratesBuy$195
4 Aug 2026Morgan StanleyMaintainsOverweight$175 → $185
4 Aug 2026Morgan StanleyMaintainsOverweight—
4 Aug 2026Piper SandlerMaintainsOverweight—
4 Aug 2026Piper SandlerMaintainsOverweight$135 → $193
4 Aug 2026Stephens & Co.MaintainsOverweight—
4 Aug 2026Stephens & Co.MaintainsOverweight$170 → $195
3 Aug 2026StifelMaintainsBuy$130 → $180
3 Aug 2026StifelMaintainsBuy—
31 July 2026BarclaysMaintainsOverweight—
31 July 2026BarclaysMaintainsOverweight$150 → $200
31 July 2026BTIGMaintainsBuy—
31 July 2026BTIGMaintainsBuy$190 → $195
31 July 2026JP MorganMaintainsOverweight$185 → $195
31 July 2026JP MorganMaintainsOverweight—
31 July 2026MizuhoMaintainsOutperform—
31 July 2026MizuhoMaintainsOutperform$175 → $200
31 July 2026RBC CapitalMaintainsOutperform—
31 July 2026RBC CapitalMaintainsOutperform$185 → $200

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Guardant Health, Inc. returned +173.9% against +18.5% for the S&P 500, dividends included.

GH vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26GHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
10
Fundamentals

Guardant Health, Inc. (GH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−49.8×

Cheaper than 98% of US stocks

Price / sales
18.6×

Cheaper than 10% of US stocks

Price / book
−98.6×

Cheaper than 99% of US stocks

EV / EBITDA
−51.8×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
44.3%

Higher than 84% of US stocks

Earnings growth (YoY)
44.3%

Higher than 73% of US stocks

Gross margin
65.4%

Higher than 79% of US stocks

Operating margin
−38.2%

Higher than 18% of US stocks

Net margin
−38.3%

Higher than 12% of US stocks

Returns & dividend
Return on equity
419.2%

Higher than 99% of US stocks

Return on assets
−18.1%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Guardant Health, Inc. (GH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Guardant Health, Inc. has a market value of $21.7B and an enterprise value of $22.3B.

  • Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 44.3% year on year.

  • Net income over the same four quarters: −$453.4M, a −38.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.49.

  • Free cash flow in the twelve months to 30 June 2026: −$240.7M.

  • Guardant Health, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 133.6M.

  • Trailing P/E: −49.8×; forward P/E: −370.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Guardant Health, Inc. employs 2,490 people — $475K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

GH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
GHGuardant Health, Inc.$21.7B
48
MEDPMedpace Holdings, Inc.$16.9B
97
DGXQuest Diagnostics, Inc.$26.2B
94
LHLabcorp Holdings, Inc.$26.9B
86
MTDMettler-Toledo International, Inc.$27.1B
91
RVTYRevvity, Inc.$14.2B
93
CRLCharles River Laboratories International, Inc.$13.8B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Guardant Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GH news & analysis

Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

Business Wire · 9 Sept 2026positive

Guardant Health and its research collaborators announced they will present 20 abstracts, including one mini oral presentation, at the 2026 World Conference on Lung Cancer. The presentations will showcase advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes.

Why it matters — This highlights Guardant Health's continued research activity and visibility in lung cancer detection and treatment management at a major international oncology conference.

Business Insider Names Guardant Health One of America's Most Innovative Businesses

Business Wire · 8 Sept 2026positive

Guardant Health announced it was named to Business Insider's America's Most Innovative Businesses 2027 list, receiving a five-star recognition that was awarded to only 12 other biotechnology research companies in the category. The inaugural list recognizes companies for their innovative performance over the preceding five years.

Why it matters — A five-star innovation rating from a major publication highlights Guardant Health's recognized track record of innovation among biotech research companies.

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Business Wire · 4 Sept 2026positive

Guardant Health announced that the FDA approved its Guardant360 CDx as a companion diagnostic to identify patients with HR-positive, HER2-negative advanced or metastatic breast cancer who have ESR1-mutated tumors and may benefit from AstraZeneca's ETCAMAH (camizestrant).

Why it matters — The approval expands the clinical use cases and market reach of Guardant Health's liquid biopsy companion diagnostic platform.

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Benzinga · 1 Sept 2026neutral

Moderna and Merck reported positive Phase 3 results for a personalized mRNA cancer vaccine. The results could revive investor interest in genomics, immunotherapy, and precision medicine ETFs.

Why it matters — Renewed interest in genomics and precision medicine ETFs could draw attention to the sector in which Guardant Health operates.

Guardant Health's Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening

Business Wire · 1 Sept 2026positive

Guardant Health announced that its Shield blood test for colorectal cancer screening will be covered under Carelon Healthcare Services clinical guidelines effective November 15. Carelon, one of the largest specialty benefits managers in the U.S., is a subsidiary of a major health insurance company operating across more than 14 states.

Why it matters — A GH watcher would care because coverage in Carelon's clinical guidelines could broaden patient access to the Shield test across a large portion of the U.S. insurance market.

FAQ

Frequently asked questions about GH stock

What is the GH stock price forecast for 2026-2027?

The 25 Wall Street analysts covering Guardant Health, Inc. have a median 12-month price target of $195, with estimates ranging from $105 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GH stock a buy right now?

Of the 25 analysts covering Guardant Health, Inc., 24 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Guardant Health, Inc. 48 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GH?

As at 8 Sept 2026, Guardant Health, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will GH stock go up?

No one can know that. What the data says: the median 12-month target from 25 analysts implies +19.8% from the last close, and Ticker Nerd's factor model ranks Guardant Health, Inc. 48 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GH stock forecast for 2030?

No analyst covering Guardant Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $105 to $225 over the next 12 months.

How has GH stock performed over the past year?

Guardant Health, Inc. returned +173.9% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Guardant Health, Inc. do?

Guardant Health Inc. is a precision oncology company that develops blood- and tissue-based tests, data sets, and analytics to support cancer detection and treatment decisions.

What is the latest news on GH?

The most recent item we track (Business Wire, 9 Sept 2026): "Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer". Guardant Health and its research collaborators announced they will present 20 abstracts, including one mini oral presentation, at the 2026 World Conference on Lung Cancer. The presentations will showcase advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes.

Company

About Guardant Health, Inc.

Guardant Health Inc. is a precision oncology company that develops blood- and tissue-based tests, data sets, and analytics to support cancer detection and treatment decisions. Its product portfolio includes liquid biopsy tests for tumor mutation profiling, molecular residual disease monitoring, tissue-based genomic profiling, and colorectal cancer screening. The company’s solutions are used across clinical care and research settings to help identify biomarkers, track recurrence, and provide molecular insights from tumor-derived material. Guardant Health serves healthcare providers, laboratories, researchers, and life sciences partners in the United States and internationally, with a focus on noninvasive diagnostics and cancer monitoring. Headquartered in Palo Alto, California, Guardant Health plays a significant role in the growing market for precision medicine and advanced oncology diagnostics.

CEO Dr. Helmy Eltoukhy Ph.D. · 2,490 employees · United States · https://guardanthealth.com